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Background: Blepharospasm is typically diagnosed by excluding any secondary
diseases and neuropsychiatric disorders, as specific tests for blepharospasm are
currently unavailable. Since anticholinergic agents are used to improve the symptoms of
dystonia, we hypothesized that edrophonium chloride, an acetylcholinesterase inhibitor,
may make the symptoms of dystonia more apparent. Therefore, we examined whether
an edrophonium challenge test would be useful for diagnosing blepharospasm.
Methods: We studied 10 patients with blepharospasm and 10 with hemifacial spasms
(as disease controls). We administered edrophonium and saline in this double-blind study.
Before and after the injection, we recorded the clinical signs using a video camera to
assess the objective symptoms every 2 min. Ten minutes after the isotonic sodium
chloride and edrophonium injections, the patients evaluated their subjective signs using
a visual analog scale (VAS). The objective signs on the video recordings were scored by
specialists who were blind to the treatment.
Results: The subjective and objective signs of the patients with blepharospasm were
amplified by edrophonium. In contrast, the signs in patients with hemifacial spasms were
not changed by the edrophonium challenge test.
Conclusions: The edrophonium challenge test may be used to diagnose
blepharospasm. The study was registered with a ICMJE recognized registry, the
UMIN-CTR, with the number UMIN000022557.
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INTRODUCTION
Dystonia is a clinical syndrome characterized by sustained muscle contractions that cause twisting
and repetitive movements or abnormal postures (Fahn et al., 1998). Blepharospasm, which presents
with abnormal eyelid closure, is caused by dystonia of the eyelids. In the clinic, blepharospasm is
typically diagnosed by excluding any secondary diseases and neuropsychiatric disorders because
of the unavailability of specific tests for blepharospasm. Usually, differential diagnosis can be
performed easily by observing the symptoms, but sometimes the differences are difficult to identify
because of the complicated symptoms of blepharospasm (Roberts et al., 2002; Hara et al., 2007).
For example, in a previously encountered case, we administered an edrophonium injection to a
patient with abnormal eyelid closure and diplopia, which resulted in improvement of the diplopia,
but amplification of the abnormal eyelid closure. Complications of myasthenia gravis (MG) and
blepharospasmwere suspected in that case. Eyelid closure dysfunction inMG is related to abnormal
functioning of the levator palpebrae superioris muscle due to deficient cholinergic transmission at
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the neuromuscular junction, while in blepharospasm, eyelid
closure dysfunction is due to the strong involuntary contraction
of the orbicularis oculi muscle.
In MG, the administration of edrophonium induces
acetylcholine release, which then improves the symptoms.
Thus, the edrophonium challenge test has been established as
a diagnostic tool for MG. However, involuntary contraction of
the orbicularis oculi muscle occurs due to blepharospasm or
hemifacial spasm among other disorders. Although the clinical
symptoms of hemifacial spasms resemble the symptoms of
blepharospasm, the causes differ. Therefore, identifying the
underlying causes of the spasms can help clinicians make an
accurate diagnosis.
Edrophonium chloride is an acetylcholinesterase inhibitor
with a rapid onset (approximately 30 s) and short duration
(approximately 5 min). Suppression of dysfunctional eyelid
closure by edrophonium is used to diagnoseMG (Pascuzzi, 2003).
Edrophonium is hydrophilic, with a limited capacity to cross
the blood–brain barrier. In addition, edrophonium is rapidly
excreted by the kidneys, suggesting limited direct efficacy in the
central nervous system (Back and Calvey, 1972; Calvey et al.,
1976; Gemmill et al., 1988). However, in our case, blepharospasm
was amplified after administering the edrophonium injection,
which suggests that edrophonium may be used to diagnose
blepharospasm.
For the medical treatment of dystonia, Balash and Giladi
concluded that high doses of trihexyphenidyl (anticholinergic
agent) are effective, especially in the treatment of segmental and
generalized dystonia in young patients (Balash and Giladi, 2004).
Because it has been reported that anticholinergic agents improve
the symptoms of dystonia, if the dysfunctional eyelid closure is
caused by blepharospasm, then the symptomsmay bemademore
apparent by edrophonium.
In this study, we examined whether an edrophonium
challenge test would be useful for diagnosing blepharospasm. To
accomplish this, we examined the clinical symptoms of 10 cases
of blepharospasm after administering edrophonium injections.
We also administered physiological saline as a control and
examined cases with hemifacial spasms as a disease control.
METHODS
Participants
The study included 10 patients with blepharospasm (2 men and
8 women; age range, 34–77 years; mean [standard deviation] age,
65.1 [11.9] years) and 10 patients with hemifacial spasms (4 men
and 6 women; age range, 46–78 years; mean [standard deviation]
age, 65.3 [9.1] years), who constituted the control group
(Table 1). All participants were examined by a single movement
disorder specialist (ShinichiMatsumoto), who performed general
physical and neurological examinations, laboratory tests, and
brain magnetic resonance imaging in order to exclude other
causes of dystonia, including birth injury and head trauma. The
patients with a history of heart disease and arrhythmia were
excluded from participating in the study for their safety. All
subjects underwent a 12-lead electrocardiogram examination and
a chest X-ray before the study to exclude the presence of cardiac
TABLE 1 | Clinical characteristics of patients with blepharospasm and
hemifacial spasms.
No. of subjects (female) Age (SD)* Age of onset
(SD)
Blepharospasm 10 (8) 65.1 (11.9) 57.0 (13.0)
Hemifacial spasms 10 (6) 65.3 (9.1) 59.0 (11.5)
*Standard deviation.
disease. This investigation was approved by the institutional
ethics committee of Shinko Hospital. Written informed consent
was obtained from all participants.
Administration of Edrophonium and
Evaluation of Subjective Symptoms
This was a double-blind study, as both the participants and
evaluators were blind to the identity of the drug (saline
or edrophonium). The protocol used for the edrophonium
challenge test is shown in the Table 2. First, we intravenously
injected isotonic sodium chloride (10 mL). Before and after the
injection, we recorded the clinical symptoms with a video camera
to assess the objective signs every 2 min (each video was 1 min
long). Tenminutes after isotonic saline injection, the participants
evaluated their subjective signs on a visual analog scale
(VAS) (Mantha et al., 1993). We explained to the participants
that the “left end” of the scale indicated the worst possible
state, while the “right end” indicated a healthy state without
blepharospasm or hemifacial spasm. Next, we administered
edrophonium (10mg in 9mL of isotonic saline) and recorded
the clinical signs as described above. Patients were directed
to self-evaluate their signs separately from any side effects
(Supplementary Videos 1, 2).
Evaluation of Objective Symptoms
Three movement disorder specialists (Nagahisa Murakami,
Hidetaka Koizumi, and Masatoshi Takahashi), who were blind to
the treatment and the purpose of the examination, independently
evaluated the objective symptoms from the videos after the
administration of the isotonic sodium chloride solution and
edrophonium, which were randomly named A and B. We
found that the symptoms changed the most around 8 min
after edrophonium administration. For this reason, we chose
to evaluate the 1-min videos that were acquired at 8 min
after administration. We presented videos of “before and after
injection of A or B” as a set. We randomly presented the “before
and after injection of A or B” videos for blepharospasm and
hemifacial spasm.
We used a modified VAS (mVAS) to evaluate the pre-
administration baseline, which was set at 50 mm (midline);
amelioration and exacerbation of symptoms were indicated by
lower and higher numbers on the mVAS, respectively. The
Jankovic score is often used to evaluate blepharospasm (Jankovic
et al., 1982) and consists of 5 stages for both the frequency score
and the severity score. However, clinically, the difference between
the frequency score and the severity score was not clear, thus
it really only evaluated five levels instead of 10. Because the
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TABLE 2 | The protocol for administering the edrophonium challenge test
in patients with movement disorders.
EVALUATION OF PATIENT SYMPTOMS
1. Videotape (1 min) recording of objective symptoms before injection
2. Normal saline injection
3. 2 min after injection: videotape recording
4. 4 min after injection: videotape recording
5. 6 min after injection: videotape recording
6. 8 min after injection: videotape recording
7. 10 min after injection: videotape recording
8. Visual analog scale (VAS) test (evaluation after normal saline injection)
9. Edrophonium injection
10. 2 min after injection: videotape recording
11. 4 min after injection: videotape recording
12. 6 min after injection: videotape recording
13. 8 min after injection: videotape recording
14. 10 min after injection: videotape recording
15. VAS test (evaluation after edrophonium injection)
EVALUATION OF THE VIDEO BY THREE MOVEMENT DISORDER
SPECIALISTS
1. We chose videos of the isotonic sodium chloride solution and edrophonium
injections, randomly referred to as A or B
2. We chose the video acquired at 8 min after administration as A or B Because
the symptoms changed the most around 8 min after edrophonium administration
3. The before injection video is shown
4. The after A injection video is shown
5. Modified VAS (the value of after A injection with before injection as midline)
6. The before injection video is shown
7. The after B injection video is shown
8. Modified VAS (the value of after B injection with before injection as midline) We
evaluated “before and after A or B injection” as a set, as described above We
randomly presented “before and after A or B injection” videos of blepharospasm
and hemifacial spasm
Jankovic score was not suitable for evaluating the fine changes
in blepharospasm after the edrophonium injection, we used
the mVAS for the evaluations. In addition, because hemifacial
spasms cannot be evaluated using the Jankovic score, we required
another evaluation method.
The final control and drug mVAS scores for each patient were
the sum of each specialist’s score. The VAS and mVAS scores
were measured from the right side, with a higher score indicating
symptoms that were more severe.
Statistical Analyses
Mean VAS and mVAS scores were compared using the Wilcoxon
rank sum test for paired continuous variables. We calculated
the relative value as follows: VAS score after edrophonium
injection—VAS score after saline injection. The relative values
were also compared using the Wilcoxon rank sum test for paired
continuous variables. All statistical tests were two-sided, and
P-values less than 0.05 were considered statistically significant.
Statistical analyses were performed using the SPSS statistical
software (version 11.0 for Windows; IBM Corporation, Armonk,
NY, USA).
RESULTS
No serious muscarinic side effects such as bronchospasm and
bradycardia were observed in this study. Typical muscarinic
side effects (increased sweating, lacrimation, salivation, nausea,
and diarrhea) were observed in all patients with blepharospasm
within the first minute. These side effects did not always
appear when the edrophonium injection was administered
to patients with hemifacial spasms. The VAS scores of the
subjective signs and the mVAS scores of the objective signs
are presented in Figures 1, 2 respectively. Involuntary eyelid
movements became obvious 4–8 min after edrophonium
injection. In patients with blepharospasm, the VAS scores for
the subjective signs and the mVAS scores for the objective
signs were significantly higher after edrophonium injection
than they were after saline injection (Figure 1). In patients
with hemifacial spasms, no statistically significant difference
was observed between the VAS and mVAS scores in the
edrophonium injection and placebo groups (Figure 2). The
relative values were significantly higher in patients with
blepharospasm than they were in patients with hemifacial spasms
(Figure 3).
DISCUSSION
We examined whether the signs of blepharospasm were
amplified by edrophonium in this preliminary study. Both
the subjective and objective signs of blepharospasm were
amplified by edrophonium administration; in contrast, the
signs of hemifacial spasm did not change after edrophonium
administration. Moreover, typical muscarinic side effects were
observed in all patients with blepharospasm. Collectively,
these findings suggest that this challenge test may help to
distinguish focal eyelid dystonia from other abnormal eye closing
syndromes.
We also found that both the subjective and objective relative
values were significantly higher in blepharospasm than they were
in hemifacial spasm. Thus, comparing symptoms at the time of
the saline injection may result in a more accurate diagnosis.
Edrophonium is a strong cholinergic drug; therefore,
side effects such as bradycardia can occur following its
administration. When conducting this study, we performed
tests to exclude patients with heart disease, hence no serious
muscarinic side effects were observed.
However, unlike the patients with hemifacial spasm, typical
muscarinic side effects (increased sweating, lacrimation, and
salivation) were observed in all patients with blepharospasm
within the first minute. It has been reported that dystonia is
caused by a mismatch between motor and sensory signals. The
strong reaction against the edrophonium and the typical
side effects that were observed following edrophonium
administration may be signs of dystonia.
As mentioned previously, eyelid closure dysfunction is
caused by abnormal functioning of the levator palpebrae
superioris muscle or involuntary contraction of the orbicularis
oculi muscle. In particular, abnormal functioning of the
levator palpebrae superioris muscle is due to muscle disease,
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FIGURE 1 | Mean and SD*1 values of the VAS*2 for the placebo injection session and the edrophonium injection session in patients with
blepharospasm. (A) The VAS scores for the subjective symptoms after edrophonium injection were significantly higher than the scores after placebo injection
(P = 0.005). (B) The modified VAS scores of the objective symptoms after edrophonium injection were significantly higher than the scores after placebo injection
(P = 0.005).
FIGURE 2 | Mean and SD*1 values of the VAS*2 for the placebo injection session and the edrophonium injection session in patients with hemifacial
spasm. There were no statistically significant differences in the VAS scores and modified VAS scores of patients with hemifacial spasms between the edrophonium
and placebo injection groups.
neuromuscular junction disease, or peripheral nerve disease.
Our diagnoses are based on the results of blood tests,
brain imaging studies, and electrophysiological tests. Since the
edrophonium test has been established for diagnosing MG,
we also examined patients with MG using the protocol of
this study. However, we only examined three cases, because
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FIGURE 3 | Mean and SD*1 of the relative values for the hemifacial spasm and blepharospasm. The VAS scores for the relative value of the subjective and
objective symptoms in patients with blepharospasm were significantly higher than the scores in patients with hemifacial spasm (P = 0.005).
performing the edrophonium test in these patients takes longer
than usual. We found that these three cases showed a tendency
to improve following the edrophonium test (data not shown),
similar to the results of previous studies (Juel and Massey,
2007).
On the other hand, involuntary contraction of the orbicularis
oculi muscle occurs due to blepharospasm or hemifacial spasm.
We did not observe changes in the symptoms of patients with
hemifacial spasm. There is now considerable evidence that
primary hemifacial spasms are, in almost all cases, related to the
vascular compression of the facial nerve at its root exit zone
from the brainstem (Abbruzzese et al., 2011). Cholinesterase
inhibitors have been shown to improve the symptoms in
patients with neuromuscular junction disorders, but they do not
act on peripheral nerve diseases. Therefore, for patients with
hemifacial spasms, it was predicted that the symptoms would
not change, which is not contradictory to our findings. These
results suggest that the edrophonium challenge test is helpful
for distinguishing blepharospasm from bilateral hemifacial
spasm.
The obvious symptoms induced by edrophonium are indirect
proof that the anticholinergic drug is effective in patients
who are edrophonium responders. It has been reported that
eyelid closure improved following edrophonium injections that
were administered for complications of MG and blepharospasm
(Funakawa et al., 1992). In this case, the symptom improved by
administering cholinergic drugs. Further research is necessary to
establish whether the patients in whom the symptoms became
obvious by edrophonium would respond to anticholinergic
agents or not.
Multiple forms of dystonia are associated with genetic
mutations, but the pathogenesis of sporadic dystonia is usually
unclear. Abnormal plasticity in the basal ganglia (BG) is believed
to be important to disease etiology, and acetylcholine is a critical
neuromodulator in the BG (Peterson et al., 2010). There are two
possible sites of action for edrophonium: the central nervous
system (including the BG) or the peripheral nerves (Jankovic,
2009).
Edrophonium is hydrophilic and has limited capacity to
cross the blood–brain barrier. In addition, edrophonium is
rapidly excreted by the kidney, suggesting limited direct
efficacy in the central nervous system (Back and Calvey,
1972; Calvey et al., 1976; Gemmill et al., 1988). It has been
reported that edrophonium mitigates allodynia in an animal
model of neuropathic pain, suggesting changes in afferent
fiber transmission to the spinal cord that could in turn alter
central sensorimotor integration (Hwang et al., 1999). The
effects of edrophonium on the neuromuscular junction and
autonomic ganglia have been studied, but those on the central
nervous system have not been studied. In this study, dystonia
became obvious 4–8 min after the edrophonium injection was
administered, while the symptoms of MG improved within 1
min. This delay suggests that the effects of edrophonium on
blepharospasm are centrally mediated by changes in afferent
input.
In conclusion, we demonstrated that the edrophonium
challenge test is helpful for distinguishing blepharospasm from
hemifacial spasm. Using the edrophonium challenge test can
help reduce misdiagnoses and improve treatment efficacy.
However, because of the small sample size and the fact
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that we did not randomize the order of the saline and
edrophonium treatments, independent replication of this study
with a larger sample size and treatment randomization is
warranted.
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